Effectiveness and Safety After a Switch to Tildrakizumab : A Real World Multicenter Italian Study in Psoriasis
INTRODUCTION: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis.
OBJECTIVES: This study aimed to evaluate the effectiveness, safety and survival of tildrakizumab in the medium term (48 weeks) in psoriatic patients failure to previous biologic treatment in a real world setting.
METHODS: This was a retrospective, multicenter observational study that included adult patients with moderate-to-severe plaque psoriasis, failure to previous biologic therapy, consecutively treated with tildrakizumab. Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) values were recorded at baseline, at 12 and 48 weeks of treatment. Safety and tolerability of tildrakizumab were investigated by examining the presence of any adverse events.
RESULTS: Overall 51 patients were enrolled. Baseline disease severity was moderate to severe with a mean PASI score of 19.2 ± 8.5, mean BSA of 16 ± 10.4, and mean Dermatology Life Quality Index (DLQI) of 18.2 ± 6.8. A significant reduction in the mean PASI score was detected at 12 weeks of tildrakizumab therapy (3.5 ± 2.7, P < 0.001), with a further improvement at week 48 (0.6 ± 1.5, P < 0.001). At week 12, there was a great improvement in BSA score for all groups (P <0.001) with further increase at week 48. The effectiveness was confirmed also by DLQI assessment, with a significant decrease at week 12 and even more at week 48 (P <0.001).
CONCLUSIONS: This study confirms the effectiveness of tildrakizumab in daily clinical practice in patients with moderate-to-severe plaque psoriasis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Dermatology practical & conceptual - 13(2023), 4 vom: 01. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Brizzi, Eugenia Veronica [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 24.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5826/dpc.1304a215 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36483658X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36483658X | ||
| 003 | DE-627 | ||
| 005 | 20231226100317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5826/dpc.1304a215 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM36483658X | ||
| 035 | |a (NLM)37992389 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Brizzi, Eugenia Veronica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and Safety After a Switch to Tildrakizumab |b A Real World Multicenter Italian Study in Psoriasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis | ||
| 520 | |a OBJECTIVES: This study aimed to evaluate the effectiveness, safety and survival of tildrakizumab in the medium term (48 weeks) in psoriatic patients failure to previous biologic treatment in a real world setting | ||
| 520 | |a METHODS: This was a retrospective, multicenter observational study that included adult patients with moderate-to-severe plaque psoriasis, failure to previous biologic therapy, consecutively treated with tildrakizumab. Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) values were recorded at baseline, at 12 and 48 weeks of treatment. Safety and tolerability of tildrakizumab were investigated by examining the presence of any adverse events | ||
| 520 | |a RESULTS: Overall 51 patients were enrolled. Baseline disease severity was moderate to severe with a mean PASI score of 19.2 ± 8.5, mean BSA of 16 ± 10.4, and mean Dermatology Life Quality Index (DLQI) of 18.2 ± 6.8. A significant reduction in the mean PASI score was detected at 12 weeks of tildrakizumab therapy (3.5 ± 2.7, P < 0.001), with a further improvement at week 48 (0.6 ± 1.5, P < 0.001). At week 12, there was a great improvement in BSA score for all groups (P <0.001) with further increase at week 48. The effectiveness was confirmed also by DLQI assessment, with a significant decrease at week 12 and even more at week 48 (P <0.001) | ||
| 520 | |a CONCLUSIONS: This study confirms the effectiveness of tildrakizumab in daily clinical practice in patients with moderate-to-severe plaque psoriasis | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Buononato, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Benvenuto, Pierfrancesco |e verfasserin |4 aut | |
| 700 | 1 | |a Argenziano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a De Pasquale, Rocco |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorella, Carmen Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Giofrè, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Musumeci, Maria Letizia |e verfasserin |4 aut | |
| 700 | 1 | |a Palazzo, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Zichichi, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Balato, Anna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatology practical & conceptual |d 2011 |g 13(2023), 4 vom: 01. Okt. |w (DE-627)NLM228504201 |x 2160-9381 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |g day:01 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5826/dpc.1304a215 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 |b 01 |c 10 | ||